Outlook Therapeutics Inc (OTLK) FinancialsOTLKOutlook Therapeutics Inc

Evaluating the bottom line, Outlook Therapeutics Inc maintains a gross margin of -95.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -124255.28%, while the net margin is -233554.85%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively OTLK converts its operational activities into shareholder value.

In the context of the broader market, OTLK competes directly with industry leaders such as NERV and PYPD. With a market capitalization of $112.50M, it holds a significant position in the sector. When comparing efficiency, OTLK's gross margin of -95.00% stands against NERV's N/A and PYPD's N/A. Such benchmarking helps identify whether Outlook Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Outlook Therapeutics has shown erratic financial performance, with total revenue fluctuating and a significant net loss of $20.3 million reported for Q3 2026. The gross margin has also turned negative, reaching -95% in the latest quarter, indicating severe challenges in profitability.